Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 505

1.

Cardiomyopathy in children with mitochondrial disease: Prognosis and genetic background.

Imai-Okazaki A, Kishita Y, Kohda M, Mizuno Y, Fushimi T, Matsunaga A, Yatsuka Y, Hirata T, Harashima H, Takeda A, Nakaya A, Sakata Y, Kogaki S, Ohtake A, Murayama K, Okazaki Y.

Int J Cardiol. 2019 Mar 15;279:115-121. doi: 10.1016/j.ijcard.2019.01.017. Epub 2019 Jan 5.

PMID:
30642647
2.

Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo.

Sato Y, Hashiba K, Sasaki K, Maeki M, Tokeshi M, Harashima H.

J Control Release. 2019 Feb 10;295:140-152. doi: 10.1016/j.jconrel.2019.01.001. Epub 2019 Jan 2.

PMID:
30610950
3.

Mitochondrial ribosomal protein PTCD3 mutations cause oxidative phosphorylation defects with Leigh syndrome.

Borna NN, Kishita Y, Kohda M, Lim SC, Shimura M, Wu Y, Mogushi K, Yatsuka Y, Harashima H, Hisatomi Y, Fushimi T, Ichimoto K, Murayama K, Ohtake A, Okazaki Y.

Neurogenetics. 2019 Jan 3. doi: 10.1007/s10048-018-0561-9. [Epub ahead of print]

PMID:
30607703
4.

Mixing lipids to manipulate the ionization status of lipid nanoparticles for specific tissue targeting.

Shobaki N, Sato Y, Harashima H.

Int J Nanomedicine. 2018 Dec 10;13:8395-8410. doi: 10.2147/IJN.S188016. eCollection 2018.

5.

The delivery of mRNA to colon inflammatory lesions by lipid-nano-particles containing environmentally-sensitive lipid-like materials with oleic acid scaffolds.

Tanaka H, Watanabe A, Konishi M, Nakai Y, Yoshioka H, Ohkawara T, Takeda H, Harashima H, Akita H.

Heliyon. 2018 Dec 3;4(12):e00959. doi: 10.1016/j.heliyon.2018.e00959. eCollection 2018 Dec.

6.

Effective Therapy Using a Liposomal siRNA that Targets the Tumor Vasculature in a Model Murine Breast Cancer with Lung Metastasis.

Sakurai Y, Hada T, Kato A, Hagino Y, Mizumura W, Harashima H.

Mol Ther Oncolytics. 2018 Oct 30;11:102-108. doi: 10.1016/j.omto.2018.10.004. eCollection 2018 Dec 21.

7.

Genome-wide identification of RETINOBLASTOMA RELATED 1 binding sites in Arabidopsis reveals novel DNA damage regulators.

Bouyer D, Heese M, Chen P, Harashima H, Roudier F, Grüttner C, Schnittger A.

PLoS Genet. 2018 Nov 30;14(11):e1007797. doi: 10.1371/journal.pgen.1007797. eCollection 2018 Nov.

8.

Critical parameters dictating efficiency of membrane-mediated drug transfer using nanoparticles.

Abbasi S, Kajimoto K, Harashima H.

Int J Pharm. 2018 Dec 20;553(1-2):398-407. doi: 10.1016/j.ijpharm.2018.10.042. Epub 2018 Oct 26.

PMID:
30393168
9.

Application of BCG-CWS as a Systemic Adjuvant by Using Nanoparticulation Technology.

Masuda H, Nakamura T, Noma Y, Harashima H.

Mol Pharm. 2018 Nov 8. doi: 10.1021/acs.molpharmaceut.8b00919. [Epub ahead of print]

PMID:
30380885
10.

Optimization of siRNA delivery to target sites: issues and future directions.

Khalil IA, Yamada Y, Harashima H.

Expert Opin Drug Deliv. 2018 Nov;15(11):1053-1065. doi: 10.1080/17425247.2018.1520836. Epub 2018 Sep 25.

PMID:
30198792
11.

DNA-loaded nano-adjuvant formed with a vitamin E-scaffold intracellular environmentally-responsive lipid-like material for cancer immunotherapy.

Kawai M, Nakamura T, Miura N, Maeta M, Tanaka H, Ueda K, Higashi K, Moribe K, Tange K, Nakai Y, Yoshioka H, Harashima H, Akita H.

Nanomedicine. 2018 Nov;14(8):2587-2597. doi: 10.1016/j.nano.2018.08.006. Epub 2018 Aug 29.

PMID:
30170077
12.

The use of cardiac progenitor cells for transplantation in congenital heart disease and an innovative strategy for activating mitochondrial function in such cells.

Abe J, Yamada Y, Harashima H.

J Thorac Dis. 2018 Jul;10(Suppl 18):S2119-S2121. doi: 10.21037/jtd.2018.06.76. No abstract available.

13.

Neutralization of negative charges of siRNA results in improved safety and efficient gene silencing activity of lipid nanoparticles loaded with high levels of siRNA.

Sato Y, Matsui H, Sato R, Harashima H.

J Control Release. 2018 Aug 28;284:179-187. doi: 10.1016/j.jconrel.2018.06.017. Epub 2018 Jun 21.

PMID:
29936118
14.

Haptic-based perception-empathy biofeedback system for balance rehabilitation in patients with chronic stroke: Concepts and initial feasibility study.

Yasuda K, Saichi K, Kaibuki N, Harashima H, Iwata H.

Gait Posture. 2018 May;62:484-489. doi: 10.1016/j.gaitpost.2018.04.013. Epub 2018 Apr 14.

PMID:
29677663
15.

A hepatic pDNA delivery system based on an intracellular environment sensitive vitamin E-scaffold lipid-like material with the aid of an anti-inflammatory drug.

Togashi R, Tanaka H, Nakamura S, Yokota H, Tange K, Nakai Y, Yoshioka H, Harashima H, Akita H.

J Control Release. 2018 Jun 10;279:262-270. doi: 10.1016/j.jconrel.2018.04.022. Epub 2018 Apr 17.

PMID:
29673647
16.

Reducing the Cytotoxicity of Lipid Nanoparticles Associated with a Fusogenic Cationic Lipid in a Natural Killer Cell Line by Introducing a Polycation-Based siRNA Core.

Nakamura T, Yamada K, Fujiwara Y, Sato Y, Harashima H.

Mol Pharm. 2018 Jun 4;15(6):2142-2150. doi: 10.1021/acs.molpharmaceut.7b01166. Epub 2018 Apr 30.

PMID:
29668291
17.

In Vivo Introduction of mRNA Encapsulated in Lipid Nanoparticles to Brain Neuronal Cells and Astrocytes via Intracerebroventricular Administration.

Tanaka H, Nakatani T, Furihata T, Tange K, Nakai Y, Yoshioka H, Harashima H, Akita H.

Mol Pharm. 2018 May 7;15(5):2060-2067. doi: 10.1021/acs.molpharmaceut.7b01084. Epub 2018 Apr 11.

PMID:
29638135
18.

Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems.

Maeki M, Kimura N, Sato Y, Harashima H, Tokeshi M.

Adv Drug Deliv Rev. 2018 Mar 15;128:84-100. doi: 10.1016/j.addr.2018.03.008. Epub 2018 Mar 19. Review.

PMID:
29567396
19.

Synergism between a cell penetrating peptide and a pH-sensitive cationic lipid in efficient gene delivery based on double-coated nanoparticles.

Khalil IA, Kimura S, Sato Y, Harashima H.

J Control Release. 2018 Apr 10;275:107-116. doi: 10.1016/j.jconrel.2018.02.016. Epub 2018 Feb 13.

PMID:
29452131
20.

Mitochondrial transgene expression via an artificial mitochondrial DNA vector in cells from a patient with a mitochondrial disease.

Ishikawa T, Somiya K, Munechika R, Harashima H, Yamada Y.

J Control Release. 2018 Mar 28;274:109-117. doi: 10.1016/j.jconrel.2018.02.005. Epub 2018 Feb 3.

PMID:
29408532
21.

An efficient PEGylated gene delivery system with improved targeting: Synergism between octaarginine and a fusogenic peptide.

Khalil IA, Harashima H.

Int J Pharm. 2018 Mar 1;538(1-2):179-187. doi: 10.1016/j.ijpharm.2018.01.007. Epub 2018 Jan 16.

PMID:
29341911
22.

Barth Syndrome: Different Approaches to Diagnosis.

Imai-Okazaki A, Kishita Y, Kohda M, Yatsuka Y, Hirata T, Mizuno Y, Harashima H, Hirono K, Ichida F, Noguchi A, Yoshida M, Tokorodani C, Nishiuchi R, Takeda A, Nakaya A, Sakata Y, Murayama K, Ohtake A, Okazaki Y.

J Pediatr. 2018 Feb;193:256-260. doi: 10.1016/j.jpeds.2017.09.075. Epub 2017 Dec 15.

PMID:
29249525
23.

Packaging of the Coenzyme Q10 into a Liposome for Mitochondrial Delivery and the Intracellular Observation in Patient Derived Mitochondrial Disease Cells.

Yamada Y, Burger L, Kawamura E, Harashima H.

Biol Pharm Bull. 2017;40(12):2183-2190. doi: 10.1248/bpb.b17-00609.

24.

Understanding the formation mechanism of lipid nanoparticles in microfluidic devices with chaotic micromixers.

Maeki M, Fujishima Y, Sato Y, Yasui T, Kaji N, Ishida A, Tani H, Baba Y, Harashima H, Tokeshi M.

PLoS One. 2017 Nov 28;12(11):e0187962. doi: 10.1371/journal.pone.0187962. eCollection 2017.

25.

Optical control of mitochondrial reductive reactions in living cells using an electron donor-acceptor linked molecule.

Takano Y, Munechika R, Biju V, Harashima H, Imahori H, Yamada Y.

Nanoscale. 2017 Dec 7;9(47):18690-18698. doi: 10.1039/c7nr06310e.

PMID:
29165486
26.

Cardiac progenitor cells activated by mitochondrial delivery of resveratrol enhance the survival of a doxorubicin-induced cardiomyopathy mouse model via the mitochondrial activation of a damaged myocardium.

Abe J, Yamada Y, Takeda A, Harashima H.

J Control Release. 2018 Jan 10;269:177-188. doi: 10.1016/j.jconrel.2017.11.024. Epub 2017 Nov 14.

PMID:
29146241
27.

Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption.

Yamamoto S, Sakurai Y, Harashima H.

Int J Pharm. 2018 Jan 30;536(1):42-49. doi: 10.1016/j.ijpharm.2017.11.010. Epub 2017 Nov 7.

PMID:
29126905
28.

Integration of nano drug-delivery system with cancer immunotherapy.

Nakamura T, Harashima H.

Ther Deliv. 2017 Nov;8(11):987-1000. doi: 10.4155/tde-2017-0071. Review.

PMID:
29061103
29.

Preparation of envelope-type lipid nanoparticles containing gold nanorods for photothermal cancer therapy.

Paraiso WKD, Tanaka H, Sato Y, Shirane D, Suzuki N, Ogra Y, Tange K, Nakai Y, Yoshioka H, Harashima H, Akita H.

Colloids Surf B Biointerfaces. 2017 Dec 1;160:715-723. doi: 10.1016/j.colsurfb.2017.10.027. Epub 2017 Oct 9.

PMID:
29035819
30.

In Vivo Transgene Expression in the Pancreas by the Intraductal Injection of Naked Plasmid DNA.

Yamada Y, Tabata M, Abe J, Nomura M, Harashima H.

J Pharm Sci. 2018 Feb;107(2):647-653. doi: 10.1016/j.xphs.2017.09.021. Epub 2017 Oct 6.

PMID:
28989012
31.

Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus.

Sato Y, Matsui H, Yamamoto N, Sato R, Munakata T, Kohara M, Harashima H.

J Control Release. 2017 Nov 28;266:216-225. doi: 10.1016/j.jconrel.2017.09.044. Epub 2017 Oct 3.

PMID:
28986168
32.

Nano-sized drug carriers: Extravasation, intratumoral distribution, and their modeling.

Nichols JW, Sakurai Y, Harashima H, Bae YH.

J Control Release. 2017 Dec 10;267:31-46. doi: 10.1016/j.jconrel.2017.08.003. Epub 2017 Aug 12. Review.

PMID:
28807683
33.

Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting.

Sakurai Y, Mizumura W, Murata M, Hada T, Yamamoto S, Ito K, Iwasaki K, Katoh T, Goto Y, Takagi A, Kohara M, Suga H, Harashima H.

Mol Pharm. 2017 Oct 2;14(10):3290-3298. doi: 10.1021/acs.molpharmaceut.7b00362. Epub 2017 Aug 25.

PMID:
28789523
34.

pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes.

Hashiba K, Sato Y, Harashima H.

J Control Release. 2017 Sep 28;262:239-246. doi: 10.1016/j.jconrel.2017.07.046. Epub 2017 Aug 1.

PMID:
28774839
35.

Size-Dependency of the Surface Ligand Density of Liposomes Prepared by Post-insertion.

Lee SH, Sato Y, Hyodo M, Harashima H.

Biol Pharm Bull. 2017;40(7):1002-1009. doi: 10.1248/bpb.b16-00990.

36.

Identification and Evaluation of the Minimum Unit of a KALA Peptide Required for Gene Delivery and Immune Activation.

Miura N, Tange K, Nakai Y, Yoshioka H, Harashima H, Akita H.

J Pharm Sci. 2017 Oct;106(10):3113-3119. doi: 10.1016/j.xphs.2017.05.014. Epub 2017 May 20.

PMID:
28535977
37.

Validation of the use of an artificial mitochondrial reporter DNA vector containing a Cytomegalovirus promoter for mitochondrial transgene expression.

Yamada Y, Ishikawa T, Harashima H.

Biomaterials. 2017 Aug;136:56-66. doi: 10.1016/j.biomaterials.2017.05.016. Epub 2017 May 10.

PMID:
28521201
38.

PEGylation of the GALA Peptide Enhances the Lung-Targeting Activity of Nanocarriers That Contain Encapsulated siRNA.

Santiwarangkool S, Akita H, Nakatani T, Kusumoto K, Kimura H, Suzuki M, Nishimura M, Sato Y, Harashima H.

J Pharm Sci. 2017 Sep;106(9):2420-2427. doi: 10.1016/j.xphs.2017.04.075. Epub 2017 May 5.

PMID:
28483420
39.

Mitochondrial Delivery of Doxorubicin Using MITO-Porter Kills Drug-Resistant Renal Cancer Cells via Mitochondrial Toxicity.

Yamada Y, Munechika R, Kawamura E, Sakurai Y, Sato Y, Harashima H.

J Pharm Sci. 2017 Sep;106(9):2428-2437. doi: 10.1016/j.xphs.2017.04.058. Epub 2017 May 3.

PMID:
28478130
40.

RETINOBLASTOMA RELATED1 mediates germline entry in Arabidopsis.

Zhao X, Bramsiepe J, Van Durme M, Komaki S, Prusicki MA, Maruyama D, Forner J, Medzihradszky A, Wijnker E, Harashima H, Lu Y, Schmidt A, Guthörl D, Logroño RS, Guan Y, Pochon G, Grossniklaus U, Laux T, Higashiyama T, Lohmann JU, Nowack MK, Schnittger A.

Science. 2017 Apr 28;356(6336). pii: eaaf6532. doi: 10.1126/science.aaf6532.

PMID:
28450583
41.

The effect of a haptic biofeedback system on postural control in patients with stroke: An experimental pilot study.

Yasuda K, Kaibuki N, Harashima H, Iwata H.

Somatosens Mot Res. 2017 Jun;34(2):65-71. doi: 10.1080/08990220.2017.1292236. Epub 2017 Apr 3.

PMID:
28372470
42.

The retinoblastoma homolog RBR1 mediates localization of the repair protein RAD51 to DNA lesions in Arabidopsis.

Biedermann S, Harashima H, Chen P, Heese M, Bouyer D, Sofroni K, Schnittger A.

EMBO J. 2017 May 2;36(9):1279-1297. doi: 10.15252/embj.201694571. Epub 2017 Mar 20.

43.

Modifying Antigen-Encapsulating Liposomes with KALA Facilitates MHC Class I Antigen Presentation and Enhances Anti-tumor Effects.

Miura N, Akita H, Tateshita N, Nakamura T, Harashima H.

Mol Ther. 2017 Apr 5;25(4):1003-1013. doi: 10.1016/j.ymthe.2017.01.020. Epub 2017 Feb 22.

44.

Modality of tumor endothelial VEGFR2 silencing-mediated improvement in intratumoral distribution of lipid nanoparticles.

Yamamoto S, Kato A, Sakurai Y, Hada T, Harashima H.

J Control Release. 2017 Apr 10;251:1-10. doi: 10.1016/j.jconrel.2017.02.010. Epub 2017 Feb 10.

PMID:
28192155
45.

Scalable preparation of poly(ethylene glycol)-grafted siRNA-loaded lipid nanoparticles using a commercially available fluidic device and tangential flow filtration.

Sakurai Y, Hada T, Harashima H.

J Biomater Sci Polym Ed. 2017 Jul - Aug;28(10-12):1086-1096. doi: 10.1080/09205063.2017.1291297. Epub 2017 Feb 10.

PMID:
28157422
46.

Modifying Cationic Liposomes with Cholesteryl-PEG Prevents Their Aggregation in Human Urine and Enhances Cellular Uptake by Bladder Cancer Cells.

Nakamura T, Noma Y, Sakurai Y, Harashima H.

Biol Pharm Bull. 2017;40(2):234-237. doi: 10.1248/bpb.b16-00770.

47.

Drug Delivery Research for the Future: Expanding the Nano Horizons and Beyond.

Mitragotri S, Lammers T, Bae YH, Schwendeman S, De Smedt S, Leroux JC, Peer D, Kwon IC, Harashima H, Kikuchi A, Oh YK, Torchilin V, Hennink W, Hanes J, Park K.

J Control Release. 2017 Jan 28;246:183-184. doi: 10.1016/j.jconrel.2017.01.011. No abstract available.

PMID:
28110715
48.

WIND1 Promotes Shoot Regeneration through Transcriptional Activation of ENHANCER OF SHOOT REGENERATION1 in Arabidopsis.

Iwase A, Harashima H, Ikeuchi M, Rymen B, Ohnuma M, Komaki S, Morohashi K, Kurata T, Nakata M, Ohme-Takagi M, Grotewold E, Sugimoto K.

Plant Cell. 2017 Jan;29(1):54-69. doi: 10.1105/tpc.16.00623. Epub 2016 Dec 23.

49.

Temperature and pH sensitivity of a stabilized self-nanoemulsion formed using an ionizable lipid-like material via an oil-to-surfactant transition.

Tanaka H, Oasa S, Kinjo M, Tange K, Nakai Y, Harashima H, Akita H.

Colloids Surf B Biointerfaces. 2017 Mar 1;151:95-101. doi: 10.1016/j.colsurfb.2016.11.020. Epub 2016 Nov 18.

PMID:
27987460
50.

Supplemental Content

Loading ...
Support Center